top of page

Psychedelics in public

Psykedelika/hallusinogener i norge

While psychedelic substances such as LSD and psilocybin were relatively well known in the 60s, beyond the 70s, 80s and 90s less and less balanced information became available. Much due to the American authorities' culture war, e.g the scientific communities that conducted serious research in the field lost both funding and permits, and in the general public only relatively odd underground communities had access to the drugs.

This has changed in recent years. From being a dead and condemned field, there are now dozens of studies on psychedelics - also here in Norway - and more and more interesting and balanced material is being published both at home and abroad. Those who wish to do so can go to e.g. Amsterdam and openly buy a dose of psilocybin-containing truffles, and explore this magical and mysterious landscape on your own.


Whether it is a good idea to do this without expert guidance and a safe environment must be up to each individual. On the one hand, the experience from the Netherlands is that the open sale of these substances causes surprisingly few problems. At the same time, the experiences are both from aktuell research and other serious application that safe frameworks and expert guidance are essential to provide a "psychedelic journey" where one can allow oneself to open up completely to what is revealed, and not least to ensure good integration of the uncovered material. So-called "set" and "setting" are thus almost as important as the substance itself.

Below you will find links to articles, lectures and films about psychedelics used as medicine or tools for human growth. so you can make up your own mind before deciding whether this is for you. 

Tor Morten Kvam ved Sykehuset Østfold forsker på psilocybin mot depresjon, angst og avhengighet

Presentation by Tor-Morten Kvam, Senior doctor/psychiatrist at PsykForsk - Innovative treatment research at Nordre Østfold DPS (Hospital Østfold HF)

Jada, Bob Parsons og Lisa Ling forteller hvordan psykedelika hjalp dem med psykologiske og relasjonelle problemer. Harvard Professor, Michael Pollan forteller om muligheter og farer

Sure, Bob Parsons, and Lisa Ling tell how psychedelics helped them overcome psychological and interpersonal issues.

Harvard Professor, Michael Pollan, breaks down the risks and benefits of these mystical plants.

Facebook, 10.11.21

Roland_Griffiths_Psykedelika redserer frykt for døden for alvorlig syke og døende

In one of the largest and most rigorous clinical investigations of psychedelic drugs to date, researchers at Johns Hopkins University and New York University have found that a single dose of psilocybin—the psychoactive compound in "magic" mushrooms—substantially diminished depression and anxiety in patients with advanced cancer.

Magnus_Slagsvold_Støre prøvde psilocybinsopp/magic mushrooms

- I had a very strong revelation, says the son of prime minister, Jonas Gahr Støre.


Skavlan (TV 2), 1.10.21


Fantastic Fungi, or The MAGIC World of Mushrooms is, with its beautiful time lapse filming, a journey into the magical, mystical and medicinal world of mushrooms, as well as their power to heal, maintain and contribute to the regeneration of life on earth.

The entire film can be found on Netflix.


Psychedelics for Depression

NRK documentary, 19.7.22

A new and ground-breaking experiment examines whether psychedelic therapy can be an alternative to antidepressants in the treatment of depression. In the study, psilocybin shows faster and better results than the standard treatment with the latest generation of SSRIs. (selective serotonin reuptake inhibitors).

About ketamine for depression. Article from the hospital about ketamine treatment. DPS emergency at Kalnes has now adopted Ketamine treatment for depression and suicidal thoughts. The section is the first in the public healthcare system in Norway to use the treatment method systematically. The article was written by Anne-Grete Melkerud, and published on 12 November 2020. Last updated 26.01.2021. The Ketamin team consists of an interdisciplinary team that receives the patients: Medical professional advisor Lowan Han Stewart, specialist in psychiatry Awais Shafiq, nurse Anita Grønsveen, section leader Camilla Bjørnson and healthcare worker Øystein Eide. In addition, healthcare worker Monica Jørgensen is part of the team. Considering that no new anti-depression drugs have been launched since the 1990s, Ketamin treatment is an important supplement in the fight against a disease that affects between four and seven percent of Norway's adult population each year, says head of department Ingmar Clausen, DPS nordre Østfold. Ketamine is basically a drug that is used as an anesthetic and has a pain-relieving effect. Since the 1970s, the drug has been used as a safe anesthetic during operations. Small doses of ketamine produce a large effect. Research has shown that small doses of Ketamine have a rapid effect on two-thirds of all depression patients. Side effects in connection with the treatment are mild and transient. Ketamine has also been shown to be very effective against suicidal thoughts. Many studies describe a rapid reduction of symptoms already after a single dose of ketamine, says Clausen. The treatment method that has been developed is a collaboration between DPS emergency in the hospital at Kalnes and the adult psychiatric outpatient clinic in Moss, both of which are organized under DPS nordre Østfold. - The start of the ketamine treatment has been well planned, and we have received expert guidance from emergency medicine physician Lowan Stewart, who has extensive experience with the treatment method with ketamine from both Norway and the USA, says Clausen. Until now, treatment with Ketamine in Norway has only been given at two private clinics. - We are happy that we can now offer our patients the treatment here in the hospital, says the head of department. Head of department Ingmar Clausen and section leader Camilla Bjørnson marking the start of the treatment. About ketamine treatment: Ketamine works by renewing brain structures. The drug also normalizes the function of the frontal lobe, also called the thinking brain, as well as restores a balance between the brain's resting network and execution network. Ketamine can open up changes in the brain, so that it becomes easier for more appropriate thought patterns, feelings and behavior to take hold. Ketamine is given intravenously. The treatment lasts approximately 40 minutes and the patient is awake during the treatment. The patient will experience entering a dream-like state, which most people will find pleasant. Most people who have a response to Ketamine notice it after the first treatment, and it is common to experience a great improvement in mood within a few hours. Full effect is achieved within a day. Patients who have an effect from the treatment are initially offered six treatments over a period of two to three weeks. Thereafter, the treatment can be continued as soon as necessary. Assessment of who can receive treatment with Ketamine is done by a senior doctor in DPS acute.

bottom of page